Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge - PubMed

Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge

G P Andrews et al. Infect Immun. 1996 Jun.

Abstract

As a first step in formulating an improved plague vaccine, we developed a simple purification strategy that produced high yields of pure cell-associated and culture supernatant-derived fraction 1 capsular antigen (F1) from both avirulent Yersinia pestis C092 (Pgm- Lcr-) and an Escherichia coli F1-producing recombinant strain. Cell-associated F1 was partially purified by sequential ammonium sulfate precipitations of a sodium chloride extract of acetone-dried bacteria harvested from broth cultures. Cell-free F1 was precipitated directly from culture supernatants with a single application of 30% ammonium sulfate. By exploiting the aggregative property of F1, large quantities of purified high-molecular-weight F1 species from both cell extracts and supernatants were isolated in the void volume of a preparative gel filtration column. Highly purified, endotoxin-free F1, combined with two different adjuvants, induced very high F1 titers in mice and protected them against either subcutaneous (70 to 100% survival) or aerosol (65 to 84% survival) challenge with virulent organisms. This protection was independent of the source of the antigen and the adjuvant used. F1-induced protection against both subcutaneous and aerosol challenge was also significantly better than that conferred by immunization with the licensed killed whole-cell vaccine. Our results indicate that F1 antigen represents a major protective component of previously studied crude capsule preparations, and immunity to F1 antigen provides a primary means for the host to overcome plague infection by either the subcutaneous or respiratory route.

Similar articles

• Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.

  Goodin JL, Nellis DF, Powell BS, Vyas VV, Enama JT, Wang LC, Clark PK, Giardina SL, Adamovicz JJ, Michiel DF. Goodin JL, et al. Protein Expr Purif. 2007 May;53(1):63-79. doi: 10.1016/j.pep.2006.12.018. Epub 2006 Dec 31. Protein Expr Purif. 2007. PMID: 17293124 Free PMC article.

• Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.

  Boyer JL, Sofer-Podesta C, Ang J, Hackett NR, Chiuchiolo MJ, Senina S, Perlin D, Crystal RG. Boyer JL, et al. Hum Gene Ther. 2010 Jul;21(7):891-901. doi: 10.1089/hum.2009.148. Hum Gene Ther. 2010. PMID: 20180652 Free PMC article.

• Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.

  Anderson GW Jr, Leary SE, Williamson ED, Titball RW, Welkos SL, Worsham PL, Friedlander AM. Anderson GW Jr, et al. Infect Immun. 1996 Nov;64(11):4580-5. doi: 10.1128/iai.64.11.4580-4585.1996. Infect Immun. 1996. PMID: 8890210 Free PMC article.

• Plague vaccines and the molecular basis of immunity against Yersinia pestis.

  Quenee LE, Schneewind O. Quenee LE, et al. Hum Vaccin. 2009 Dec;5(12):817-23. doi: 10.4161/hv.9866. Epub 2009 Dec 1. Hum Vaccin. 2009. PMID: 19786842 Review.

• Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis.

  Friedlander AM, Welkos SL, Worsham PL, Andrews GP, Heath DG, Anderson GW Jr, Pitt ML, Estep J, Davis K. Friedlander AM, et al. Clin Infect Dis. 1995 Oct;21 Suppl 2:S178-81. doi: 10.1093/clinids/21.supplement_2.s178. Clin Infect Dis. 1995. PMID: 8845449 Review.

Cited by

• Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen.

  Chiuchiolo MJ, Boyer JL, Krause A, Senina S, Hackett NR, Crystal RG. Chiuchiolo MJ, et al. J Infect Dis. 2006 Nov 1;194(9):1249-57. doi: 10.1086/507644. Epub 2006 Sep 25. J Infect Dis. 2006. PMID: 17041851 Free PMC article.

• The smpB-ssrA mutant of Yersinia pestis functions as a live attenuated vaccine to protect mice against pulmonary plague infection.

  Okan NA, Mena P, Benach JL, Bliska JB, Karzai AW. Okan NA, et al. Infect Immun. 2010 Mar;78(3):1284-93. doi: 10.1128/IAI.00976-09. Epub 2010 Jan 11. Infect Immun. 2010. PMID: 20065026 Free PMC article.

• Targeting of the Yersinia pestis F1 capsular antigen by innate-like B1b cells mediates a rapid protective response against bubonic plague.

  Levy Y, Vagima Y, Tidhar A, Aftalion M, Gur D, Nili U, Chitlaru T, Zauberman A, Mamroud E. Levy Y, et al. NPJ Vaccines. 2018 Oct 19;3:52. doi: 10.1038/s41541-018-0087-z. eCollection 2018. NPJ Vaccines. 2018. PMID: 30374415 Free PMC article.

• Two decades of plant-based candidate vaccines: a review of the chimeric protein approaches.

  Soria-Guerra RE, Moreno-Fierros L, Rosales-Mendoza S. Soria-Guerra RE, et al. Plant Cell Rep. 2011 Aug;30(8):1367-82. doi: 10.1007/s00299-011-1065-3. Epub 2011 Apr 20. Plant Cell Rep. 2011. PMID: 21505834 Review.

• Intraspecific diversity of Yersinia pestis.

  Anisimov AP, Lindler LE, Pier GB. Anisimov AP, et al. Clin Microbiol Rev. 2004 Apr;17(2):434-64. doi: 10.1128/CMR.17.2.434-464.2004. Clin Microbiol Rev. 2004. PMID: 15084509 Free PMC article. Review.

References

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program